Novartis AG ADR (NVS) - Total Liabilities
Based on the latest financial reports, Novartis AG ADR (NVS) has total liabilities worth $80.09 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NVS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Novartis AG ADR - Total Liabilities Trend (1998–2025)
This chart illustrates how Novartis AG ADR's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Novartis AG ADR asset portfolio.
Novartis AG ADR Competitors by Total Liabilities
The table below lists competitors of Novartis AG ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$65.36 Billion |
|
General Electric Company
SA:GEOO34
|
Brazil | R$109.81 Billion |
|
Royal Bank of Canada
TO:RY
|
Canada | CA$2.35 Trillion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $66.63 Billion |
|
China Construction Bank Corporation
F:C6T
|
Germany | €43.49 Trillion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$79.61 Billion |
|
RTX Corporation
NYSE:RTX
|
USA | $105.83 Billion |
|
Roche Holding AG
SW:ROG
|
Switzerland | CHF62.82 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Novartis AG ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Novartis AG ADR (NVS) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Novartis AG ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Novartis AG ADR (1998–2025)
The table below shows the annual total liabilities of Novartis AG ADR from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $69.02 Billion | +18.75% |
| 2024-12-31 | $58.12 Billion | +9.26% |
| 2023-12-31 | $53.20 Billion | -8.33% |
| 2022-12-31 | $58.03 Billion | -9.29% |
| 2021-12-31 | $63.97 Billion | -15.29% |
| 2020-12-31 | $75.52 Billion | +20.14% |
| 2019-12-31 | $62.86 Billion | -6.00% |
| 2018-12-31 | $66.87 Billion | +13.63% |
| 2017-12-31 | $58.85 Billion | +6.55% |
| 2016-12-31 | $55.23 Billion | +1.47% |
| 2015-12-31 | $54.43 Billion | -0.20% |
| 2014-12-31 | $54.54 Billion | +5.33% |
| 2013-12-31 | $51.78 Billion | -5.85% |
| 2012-12-31 | $55.00 Billion | +6.67% |
| 2011-12-31 | $51.56 Billion | -3.72% |
| 2010-12-31 | $53.55 Billion | +40.76% |
| 2009-12-31 | $38.04 Billion | +36.54% |
| 2008-12-31 | $27.86 Billion | +6.93% |
| 2007-12-31 | $26.06 Billion | -2.46% |
| 2006-12-31 | $26.71 Billion | +8.73% |
| 2005-12-31 | $24.57 Billion | +19.56% |
| 2004-12-31 | $20.55 Billion | +9.31% |
| 2003-12-31 | $18.80 Billion | +12.33% |
| 2002-12-31 | $16.73 Billion | +13.47% |
| 2001-12-31 | $14.75 Billion | +13.79% |
| 2000-12-31 | $12.96 Billion | -26.64% |
| 1999-12-31 | $17.67 Billion | +0.63% |
| 1998-12-31 | $17.56 Billion | -- |
About Novartis AG ADR
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more